|
|
| (44 tussenliggende versies worden niet weergegeven) |
| Regel 1: |
Regel 1: |
| - | In onderstaande tabel staan verwijzingen naar andere richtlijnen opgesomd: | + | In onderstaande tabel staan per hoofdstuk/paragraaf verwijzingen naar andere richtlijnen vermeld:<br> |
| - | <br><div class="WordSection1"> | + | |
| - | {| cellspacing="0" cellpadding="0" border="1" style="mso-yfti-irow:0;mso-yfti-firstrow:yes" class="MsoTableGrid"
| + | {| width="100%" border="1" align="left" cellspacing="1" cellpadding="1" |
| | + | |- |
| | + | | valign="top" align="left" | '''Pagina'''<br> |
| | + | | width="45" valign="top" align="left" | '''Link naar andere richtlijn''' |
| | + | |- |
| | + | | valign="top" align="left" | [[Inhoud|'''Inhoud''']] |
| | + | | width="45" valign="top" align="left" | SOA richtlijn<br>PrEP richtlijn |
| | + | |- |
| | + | | valign="top" align="left" | '''[[Hoofdstuk 2. Therapie bij volwassenen]]<br>''' |
| | + | | width="45" valign="top" align="left" | <br> |
| | |- | | |- |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | | valign="top" align="left" | [[2.1. Wanneer beginnen?]] <br> |
| - | '''Pagina<o:p></o:p>'''
| + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | | + | |- |
| - | | width="269" valign="top" style="width:201.9pt;border:solid windowtext 1.0pt; border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt: solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | | valign="top" align="left" | [[2.2. Keuze van antiretrovirale therapie bij naïeve volwassenen met hiv|2.2. Keuze van anti-retrovirale therapie bij naïeve volwassenen met hiv]]<br> |
| - | '''Verwijzing naar andere richtlijnen<o:p></o:p>'''
| + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | | + | |- |
| - | |- style="mso-yfti-irow:1"
| + | | valign="top" align="left" | [[2.3. Tijdelijk onderbreken van antiretrovirale therapie|2.3. Tijdelijk onderbreken van anti-retrovirale therapie]]<br> |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | '''<a'''
| + | |- |
| - | | + | | valign="top" align="left" | [[2.4. Richtlijn anti-retrovirale therapie bij voorbehandelde mensen met hiv|2.4. Richtlijn anti-retrovirale therapie bij voorbehandelde mensen met hiv]]<br> |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Richtlijn%20HIV">Hoofdpagina'''
| + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | '''(=inhoudsopgave)</a><o:p></o:p>'''
| + | |- |
| - | | + | | valign="top" align="left" | '''[[Hoofdstuk 3. Behandeling van hiv-1 infectie bij kinderen|Hoofdstuk 3. Behandeling van hiv-1 infectie bij kinderen]]''' |
| - | | + | | width="45" valign="top" align="left" | Aidsinfo NIH<br>Kinderformularium |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |- |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | | valign="top" align="left" | '''[[Hoofdstuk 4. Monitoring]]<br>''' |
| - | | + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | |- style="mso-yfti-irow:2"
| + | |- |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | | valign="top" align="left" | [[4.2. Spiegelbepaling]]<br> |
| - | '''<o:p> </o:p>'''
| + | | width="45" valign="top" align="left" | Aidsinfo NIH<br>TDM-protocollen |
| - | | + | |- |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | | valign="top" align="left" | [[4.3. Resistentiebepalingen]]<br> |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | | + | |- |
| - | |- style="mso-yfti-irow:3"
| + | | valign="top" align="left" | '''[[Hoofdstuk 5. Diagnostiek en behandeling primaire hiv-infectie|Hoofdstuk 5. Diagnostiek en behandeling primaire hiv-infectie]]<br>''' |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | '''<a'''
| + | |- |
| - | | + | | valign="top" align="left" | '''[[Hoofdstuk 7. Preventie van moeder-kind overdracht: zwangerschap, bevalling en neonatale periode]]<br>''' |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%201.%20Achtergrondinformatie%20bij%20de%20ontwikkeling%20en%20herziening%20van%20deze%20richtlijn%20en%20inleiding">Hoofdstuk 1. Achtergrondinformatie bij de ontwikkeling en herziening van deze richtlijn'''
| + | | width="45" valign="top" align="left" | Aidsinfo NIH Perinatal<br> Landelijk hiv expositie protocol neonaten |
| - | '''en inleiding</a><o:p></o:p>'''
| + | |- |
| - | | + | | valign="top" align="left" | '''[[Hoofdstuk 8. HIV-2 bij volwassenen: Behandeling en monitoring]]<br>''' |
| - | | + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |- |
| - | <span style="mso-bidi-font-weight:bold">NVHB Richtlijn 2007<o:p></o:p></span>
| + | | valign="top" align="left" | '''[[Hoofdstuk 9. Bijzondere omstandigheden]]''' |
| - | | + | | width="45" valign="top" align="left" | |
| - | |- style="mso-yfti-irow:4"
| + | |- |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | | valign="top" align="left" | [[9.5. Adviezen m.b.t. gebruik anti-hiv middelen door de sonde]] |
| - | <a
| + | | width="45" valign="top" align="left" | EACS |
| - | | + | |- |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Procedure%20herziening">Procedure
| + | | valign="top" align="left" | [[9.6. Doseringen bij gestoorde leverfunctie]] |
| - | herziening</a>
| + | | width="45" valign="top" align="left" | EACS |
| - | | + | |- |
| - | | + | | valign="top" align="left" | [[9.7. Doseringen bij gestoorde nierfunctie]] |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | | width="45" valign="top" align="left" | EACS |
| - | NVHB Richtlijn 2007
| + | |- |
| - | | + | | valign="top" align="left" | '''[[Hoofdstuk 10. Behandeling van hepatitis B/C-virus coïnfectie bij mensen met hiv-1|Hoofdstuk 10. Behandeling van hepatitis B/C-virus coïnfectie bij mensen met hiv-1]]<br>''' |
| - | |- style="mso-yfti-irow:5"
| + | | width="45" valign="top" align="left" | <br> |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |- |
| - | <a
| + | | valign="top" align="left" | [[10.1. Hepatitis B]]<br> |
| - | | + | | width="45" valign="top" align="left" | Aidsinfo NIH<br>EACS |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Samenstelling%20kernwerkgroep">Samenstelling
| + | |- |
| - | kernwerkgroep</a>
| + | | valign="top" align="left" | [[10.2. Hepatitis C|10.2. Hepatitis C]] |
| - | | + | | width="45" valign="top" align="left" | HCV richtsnoer |
| - | | + | |- |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | | valign="top" align="left" | [[10.3. HCC surveillance|10.3. HCC surveillance]] |
| - | <o:p> </o:p>
| + | | width="45" valign="top" align="left" | HBV richtsnoer |
| - | | + | |- |
| - | |- style="mso-yfti-irow:6"
| + | | valign="top" align="left" | '''[[Hoofdstuk 11. Behandeling van tuberculose bij mensen met een hiv-infectie|Hoofdstuk 11. Behandeling van tuberculose bij mensen met een hiv-infectie]]<br>''' |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | | width="45" valign="top" align="left" | KNCV |
| - | <a
| + | |- |
| - | | + | | valign="top" align="left" | '''[[Hoofdstuk 12. Comorbiditeit en bijwerkingen]]<br>''' |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Overzicht%20belangen%20werkgroepleden">Overzicht
| + | | width="45" valign="top" align="left" | EACS<br> |
| - | belangen werkgroepleden</a>
| + | |- |
| - | | + | | valign="top" align="left" | '''[[Hoofdstuk 13. Screening van mensen met hiv op anogenitale maligniteiten|Hoofdstuk 13. Screening van mensen met hiv op anogenitale maligniteiten]] <br>''' |
| - | | + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |- |
| - | <o:p> </o:p>
| + | | valign="top" align="left" | [[Hoofdstuk 15. Profylaxe en behandeling van opportunistische infectie|'''Hoofdstuk 15. Profylaxe en behandeling van opportunistische infectie''']] |
| - | | + | | width="45" valign="top" align="left" | Aidsinfo NIH<br>Nationale Antibioticaboekje<br>SWAB richtlijnen |
| - | |- style="mso-yfti-irow:7"
| + | |- |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | | valign="top" align="left" | '''[[Hoofdstuk 16. Transmissiereductie (PEP)|Hoofdstuk 16. Transmissiemanagement]]<br>''' |
| - | <a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Definities">Definities</a>
| + | | width="45" valign="top" align="left" | <br> |
| - | | + | |- |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | | valign="top" align="left" | [[16.1. Prikaccidenten]]<br> |
| - | <o:p> </o:p>
| + | | width="45" valign="top" align="left" | LCI |
| - | | + | |- |
| - | |- style="mso-yfti-irow:8"
| + | | valign="top" align="left" | [[16.2. Seksaccidenten]]<br> |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | | width="45" valign="top" align="left" | LCI/RIVM |
| - | Geschiedenis per pagina van deze richtlijn (= huidige pagina)
| + | |- |
| - | | + | | valign="top" align="left" | '''[[Hoofdstuk 17. Vaccinatiebeleid]]<br>''' |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | | width="45" valign="top" align="left" | <br> |
| - | <o:p> </o:p>
| + | |- |
| - | | + | | valign="top" align="left" | [[17.2. Vaccinatie tegen influenza]] <br> |
| - | |- style="mso-yfti-irow:9"
| + | | width="45" valign="top" align="left" | RIVM<br>NHG |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |- |
| - | '''<o:p> </o:p>'''
| + | | valign="top" align="left" | [[17.4. Vaccinaties tegen Hepatitis A en B]]<br> |
| - | | + | | width="45" valign="top" align="left" | RIVM |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |- |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | | valign="top" align="left" | [https://richtlijnhiv.nvhb.nl/index.php/Addendum:%C2%A0SOA-richtlijn '''Addendum:''' SOA-richtlijn] |
| - | | + | | width="45" valign="top" align="left" | SOA richtlijn |
| - | |- style="mso-yfti-irow:10"
| + | |- |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | | valign="top" align="left" | [http://richtlijnhiv.nvhb.nl/images/2/22/PrEP-richtlijn-Nederland-8-september-2016-met-logos.pdf '''Addendum:''' Pre-exposure profylaxe (PrEP) richtlijn] |
| - | '''<a'''
| + | | width="45" valign="top" align="left" | PrEP-richtlijn |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%202.%20Therapie%20bij%20volwassenen">Hoofdstuk'''
| + | |
| - | '''2. Therapie bij volwassenen</a><o:p></o:p>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:11"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.1.%20Wanneer%20beginnen?">2.1.
| + | |
| - | Wanneer beginnen?</a> | + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:12"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20wanneer%20starten">Onderbouwing
| + | |
| - | wanneer starten</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:13" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%202.1">Literatuur
| + | |
| - | 2.1</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:14"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.2.%20Keuze%20van%20antiretrovirale%20therapie%20bij%20na%C3%AFeve%20volwassen%20pati%C3%ABnten">2.2.
| + | |
| - | Keuze van antiretrovirale therapie bij naïeve volwassen patiënten</a> | + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:15" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%202.2">Literatuur
| + | |
| - | 2.2</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:16"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.3.%20Tijdelijk%20onderbreken%20van%20HAART">2.3.
| + | |
| - | Tijdelijk onderbreken van HAART</a> | + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:17" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/T%C2%BD%20van%20antiretrovirale%20middelen">T½
| + | |
| - | van antiretrovirale middelen</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:18"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.4.%20Richtlijn%20anti-retrovirale%20therapie%20bij%20voorbehandelde%20pati%C3%ABnten">2.4.
| + | |
| - | Richtlijn <span class="SpellE">anti-retrovirale</span> therapie bij <span class="SpellE">voorbehandelde</span> patiënten</a> | + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:19" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:20"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<a''' | + | |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%203.%20Behandeling%20van%20HIV-1%20infectie%20bij%20kinderen">Hoofdstuk'''
| + | |
| - | '''3. Behandeling van HIV-1 infectie bij kinderen</a><o:p></o:p>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span class="SpellE"><span style="mso-bidi-font-weight:bold">Penta</span></span><span style="mso-bidi-font-weight:bold"><o:p></o:p></span>
| + | |
| - | | + | |
| - | <span class="SpellE"><span class="GramE"><span style="mso-bidi-font-weight: bold">Aidsinfo</span></span></span><span style="mso-bidi-font-weight:bold">
| + | |
| - | NIH<o:p></o:p></span> | + | |
| - | | + | |
| - | |- style="mso-yfti-irow:21" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | '''<o:p> </o:p>'''
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:22"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<a''' | + | |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%204.%20Monitoring">Hoofdstuk'''
| + | |
| - | '''4. Monitoring</a><o:p></o:p>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:23" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/4.1.%20Controles%20HIV-pati%C3%ABnten%20%28polikliniek%29">4.1.
| + | |
| - | Controles HIV-patiënten (polikliniek)</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:24"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Bij%20eerste%20consult%20bij%20HIV-seropositieve%20pati%C3%ABnt%20%28polikliniek%29">Bij eerste consult bij <span class="SpellE">HIV-seropositieve</span> patiënt (polikliniek)</a><a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Bij%20instellen%20op%20antiretrovirale%20therapie%20%28polikliniek%29" _fcknotitle=true _fcksavedurl="Bij instellen op antiretrovirale therapie (polikliniek)">Bij
| + | |
| - | instellen op antiretrovirale therapie (polikliniek)</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:25"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Eerste%20controle%20na%20instellen%20op%20anti-retrovirale%20therapie%204-6%20weken%20na%20start%20%28polikliniek%29">Eerste controle na instellen op <span class="SpellE">anti-retrovirale</span> therapie
| + | |
| - | 4-6 weken na start (polikliniek)</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:26" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Controle%20van%20pati%C3%ABnten%20op%20antiretrovirale%20therapie%20%28polikliniek%29">Controle
| + | |
| - | van patiënten op antiretrovirale therapie (polikliniek)</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:27"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Controle%20van%20pati%C3%ABnten%20zonder%20antiretrovirale%20therapie%20%28polikliniek%29">Controle
| + | |
| - | van patiënten zonder antiretrovirale therapie (polikliniek)</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:28"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/4.2.%20Spiegelbepaling">4.2.
| + | |
| - | Spiegelbepaling</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:29"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/4.3.%20Resistentiebepalingen">4.3.
| + | |
| - | Resistentiebepalingen</a> | + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:30" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | '''<o:p> </o:p>'''
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:31"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<a''' | + | |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%205.%20Diagnostiek%20en%20behandeling%20primaire%20HIV-infectie">Hoofdstuk'''
| + | |
| - | '''5. Diagnostiek en behandeling primaire <span class="SpellE">HIV-infectie</span></a><o:p></o:p>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span class="SpellE"><span class="GramE"><span style="mso-bidi-font-weight: bold">Aidsinfo</span></span></span><span style="mso-bidi-font-weight:bold">
| + | |
| - | NIH<o:p></o:p></span> | + | |
| - | | + | |
| - | |- style="mso-yfti-irow:32" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | '''<o:p> </o:p>'''
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:33"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<a''' | + | |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%206.%20Therapietrouw%20bevorderende%20maatregelen">Hoofdstuk'''
| + | |
| - | '''6. Therapietrouw bevorderende maatregelen</a><o:p></o:p>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:34"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/6.1.%20Therapietrouw%20be%C3%AFnvloedende%20factoren">6.1.
| + | |
| - | Therapietrouw beïnvloedende factoren</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:35"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%206.1">Literatuur
| + | |
| - | 6.1</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:36"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/6.2.%20Therapietrouw%20bevorderende%20interventies">6.2.
| + | |
| - | Therapietrouw bevorderende interventies</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:37"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20therapietrouw%20bevorderende%20interventies">Onderbouwing
| + | |
| - | therapietrouw bevorderende interventies</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:38"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%206.2">Literatuur
| + | |
| - | 6.2</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:39"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<o:p> </o:p>'''
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:40"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<a'''
| + | |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%207.%20Preventie%20van%20moeder-kind%20overdracht:%20zwangerschap,%20bevalling%20en%20neonatale%20periode">Hoofdstuk 7. Preventie van moeder-kind overdracht: zwangerschap, bevalling en neonatale'''
| + | |
| - | '''periode</a><o:p></o:p>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span class="SpellE"><span class="GramE"><span style="mso-bidi-font-weight: bold">Aidsinfo</span></span></span><span style="mso-bidi-font-weight:bold">
| + | |
| - | NIH Perinatal<o:p></o:p></span> | + | |
| - | | + | |
| - | <span style="mso-bidi-font-weight:bold">NVHB Richtlijn 2007<o:p></o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:41" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%207">Literatuur
| + | |
| - | 7</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:42"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:43"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<a''' | + | |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%208.%20HIV-2%20bij%20volwassenen:%20Behandeling%20en%20monitoring">Hoofdstuk'''
| + | |
| - | '''8. HIV-2 bij volwassenen: Behandeling en monitoring</a><o:p></o:p>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span class="SpellE"><span class="GramE"><span style="mso-bidi-font-weight: bold">Aidsinfo</span></span></span><span style="mso-bidi-font-weight:bold">
| + | |
| - | NIH<o:p></o:p></span> | + | |
| - | | + | |
| - | |- style="mso-yfti-irow:44" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%208">Literatuur
| + | |
| - | 8</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:45"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<o:p> </o:p>''' | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:46"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<a'''
| + | |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%209.%20Bijzondere%20omstandigheden">Hoofdstuk'''
| + | |
| - | '''9. Bijzondere omstandigheden</a><o:p></o:p>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:47" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.1.%20Adviezen%20m.b.t.%20inname%20van%20anti-HIV%20middelen%20na%20braken">9.1.
| + | |
| - | Adviezen m.b.t. inname van anti-HIV middelen na braken</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:48"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.2.%20Adviezen%20m.b.t.%20inname%20van%20anti-HIV%20middelen%20bij%20vergeten%20van%20slikmoment">9.2.
| + | |
| - | Adviezen m.b.t. inname van anti-HIV middelen bij vergeten van slikmoment</a> | + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:49" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.3.%20Marge%20tussen%20twee%20innames">9.3.
| + | |
| - | Marge tussen twee innames</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:50"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.4.%20Inname%20medicatie%20bij%20overschrijden%20tijdzones">9.4.
| + | |
| - | Inname medicatie bij overschrijden tijdzones</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:51" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.5.%20Adviezen%20m.b.t.%20gebruik%20anti-HIV%20middelen%20door%20de%20sonde">9.5.
| + | |
| - | Adviezen m.b.t. gebruik anti-HIV middelen door de sonde</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:52"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.6.%20Doseringen%20bij%20gestoorde%20lever-%20en%20nierfunctie">9.6.
| + | |
| - | Doseringen bij gestoorde lever- en nierfunctie</a> | + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:53" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | '''<o:p> </o:p>'''
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:54"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<a''' | + | |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2010.%20Behandeling%20van%20hepatitis%20B/C-virus%20co%C3%AFnfectie%20bij%20HIV-1%20positieve%20pati%C3%ABnten">Hoofdstuk 10. Behandeling van hepatitis B/C-virus <span class="SpellE">coïnfectie</span>'''
| + | |
| - | '''bij HIV-1 positieve patiënten</a><o:p></o:p>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span> | + | |
| - | | + | |
| - | |- style="mso-yfti-irow:55" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/10.1.%20Hepatitis%20B"><span lang="EN-US" style="mso-ansi-language:EN-US">10.1. Hepatitis B</span></a><span lang="EN-US" style="mso-ansi-language:EN-US"><o:p></o:p></span>
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | EACS | + | |
| - | | + | |
| - | |- style="mso-yfti-irow:56" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/10.2.%20Hepatitis%20C%C2%A0%28acuut%29"><span lang="EN-US" style="mso-ansi-language:EN-US">10.2. Hepatitis C (<span class="SpellE">acuut</span>)</span></a><span lang="EN-US" style="mso-ansi-language: EN-US"><o:p></o:p></span>
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | NL aanbevelingen
| + | |
| - | | + | |
| - | NEAT
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:57" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Levels%20of%20evidence"><span lang="EN-US" style="mso-ansi-language:EN-US">Levels of evidence</span></a><span lang="EN-US" style="mso-ansi-language:EN-US"><o:p></o:p></span>
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:58"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2010.2">Literatuur
| + | |
| - | 10.2</a> | + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:59"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/10.3.%20Hepatitis%20C%C2%A0%28chronisch%29">10.3.
| + | |
| - | Hepatitis C (chronisch)</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | EACS
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:60" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:61"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<a''' | + | |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2011.%20Behandeling%20van%20tuberculose%20bij%20pati%C3%ABnten%20met%20een%20HIV-infectie">Hoofdstuk'''
| + | |
| - | '''11. Behandeling van tuberculose bij patiënten met een HIV-<span class="SpellE">infectie</span></a><o:p></o:p>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span style="mso-bidi-font-weight:bold">CBO Tuberculose-HIV<o:p></o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:62" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2011">Literatuur
| + | |
| - | 11</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:63"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:64"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<a''' | + | |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2012.%20Comorbiditeit%20en%20bijwerkingen">Hoofdstuk'''
| + | |
| - | '''12. Comorbiditeit en bijwerkingen</a><o:p></o:p>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span style="mso-bidi-font-weight:bold">EACS<o:p></o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:65" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | '''<o:p> </o:p>'''
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:66"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<a''' | + | |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2013.%20Screening%20van%20HIV-pati%C3%ABnten%20op%20anogenitale%20maligniteiten">Hoofdstuk'''
| + | |
| - | '''13. Screening van HIV-patiënten op anogenitale maligniteiten</a><o:p></o:p>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:67"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20screening%20van%20HIV-pati%C3%ABnten%20op%20anogenitale%20maligniteiten">Onderbouwing
| + | |
| - | screening van HIV-patiënten op anogenitale maligniteiten</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:68"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2013">Literatuur
| + | |
| - | 13</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:69"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<o:p> </o:p>'''
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span> | + | |
| - | | + | |
| - | |- style="mso-yfti-irow:70"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<a'''
| + | |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2014.%20Interacties">Hoofdstuk'''
| + | |
| - | '''14. Interacties</a><o:p></o:p>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:71" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | '''<o:p> </o:p>'''
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:72"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<a''' | + | |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2015.%20Profylaxe%20en%20behandeling%20van%20opportunistische%20infectie">Hoofdstuk'''
| + | |
| - | '''15. Profylaxe en behandeling van opportunistische infectie</a><o:p></o:p>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span style="mso-bidi-font-weight:bold">CDC<o:p></o:p></span> | + | |
| - | | + | |
| - | <span class="GramE"><span style="mso-bidi-font-weight:bold">Nationale</span></span><span style="mso-bidi-font-weight:bold"> antibioticaboekje<o:p></o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:73" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:74"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | Hoofdstuk 16. Post Exposure Profylaxe na prikaccident en onveilig <span class="SpellE">sexueel</span> contact
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:75"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<a''' | + | |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2016.%20Transmissiereductie%20%28PEP%29">Hoofdstuk'''
| + | |
| - | '''16. <span class="GramE">Transmissiereductie</span> (PEP)</a><o:p></o:p>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span> | + | |
| - | | + | |
| - | |- style="mso-yfti-irow:76" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/16.1.%20Prikaccidenten">16.1.
| + | |
| - | Prikaccidenten</a> | + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | LCI | + | |
| - | | + | |
| - | |- style="mso-yfti-irow:77" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/16.2.%20Seksaccidenten">16.2.
| + | |
| - | Seksaccidenten</a> | + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | LCI/RIVM | + | |
| - | | + | |
| - | |- style="mso-yfti-irow:78" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | '''<o:p> </o:p>'''
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:79"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<a''' | + | |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2017.%20Vaccinatiebeleid">Hoofdstuk'''
| + | |
| - | '''17. Vaccinatiebeleid</a><o:p></o:p>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span> | + | |
| - | | + | |
| - | |- style="mso-yfti-irow:80" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.1.%20Vaccinaties%20bij%20HIV-ge%C3%AFnfecteerde%20kinderen">17.1.
| + | |
| - | Vaccinaties bij <span class="SpellE">HIV-geïnfecteerde</span> kinderen</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | CDC
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:81"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.2.%20Vaccinatie%20tegen%20influenza">17.2.
| + | |
| - | Vaccinatie tegen influenza</a> | + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | NHG Standaard | + | |
| - | | + | |
| - | |- style="mso-yfti-irow:82" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20Vaccinatie%20tegen%20influenza">Onderbouwing
| + | |
| - | Vaccinatie tegen influenza</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:83"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2017.2">Literatuur
| + | |
| - | 17.2</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:84"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.3.%20Vaccinatie%20tegen%20infecties%20met%20Streptococcus%20pneumoniae%20%28Pneumokokken%29">17.3.
| + | |
| - | Vaccinatie tegen infecties met Streptococcus pneumoniae (Pneumokokken)</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:85"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20Vaccinatie%20tegen%20infecties%20met%20Streptococcus%20pneumoniae%20%28Pneumokokken%29%20%28Pneumokokken%29">Onderbouwing Vaccinatie tegen infecties met Streptococcus pneumoniae (Pneumokokken)
| + | |
| - | (Pneumokokken)</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:86"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2017.3">Literatuur
| + | |
| - | 17.3</a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:87"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.4.%20Vaccinaties%20tegen%20Hepatitis%20A%20en%20B">17.4.
| + | |
| - | Vaccinaties tegen Hepatitis A en B</a> | + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:88" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a
| + | |
| - | | + | |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.5.%20Vaccinatie%20bij%20HIV-ge%C3%AFnfecteerde%20reizigers">17.5.
| + | |
| - | Vaccinatie bij <span class="SpellE">HIV-geïnfecteerde</span><span class="SpellE">reizigers</span></a>
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | LCR
| + | |
| - | | + | |
| - | CDC
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:89" | + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | <a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Bureau%27s%20voor%20reizigersadvisering"><span class="SpellE">Bureau's</span> voor reizigersadvisering</a>
| + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <o:p> </o:p>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:90"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | '''<o:p> </o:p>''' | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| - | |- style="mso-yfti-irow:91;mso-yfti-lastrow:yes"
| + | |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" | | + | |
| - | '''<a'''
| + | |
| - | | + | |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2018.%20Kostenoverzicht%20antiretrovirale%20middelen">Hoofdstuk'''
| + | |
| - | '''18. Kostenoverzicht antiretrovirale middelen</a>'''
| + | |
| - | | + | |
| - | | + | |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| + | |
| - | <span style="mso-bidi-font-weight:bold"><o:p> </o:p></span>
| + | |
| - | | + | |
| | |} | | |} |
| - |
| |
| - | <o:p> </o:p>
| |
| - | </div>
| |
| - | </body></html>
| |
In onderstaande tabel staan per hoofdstuk/paragraaf verwijzingen naar andere richtlijnen vermeld:
